Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation
Clinical trial NCT02044328 · COMPLETED
Trial details
- NCT number
- NCT02044328
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-01-01
- Primary completion
- 2018-01-01
- Enrollment
- 79
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.